nnc0148-0000-0362

NNC0148-0000-0362 is an investigational orally administered, long-acting insulin analogue developed by Novo Nordisk for the treatment of diabetes mellitus. It is designed as a basal insulin formulation, targeting the insulin receptor and intended to be taken orally as tablets. The drug is classified as both an antihyperglycaemic and pancreatic hormone, with primary indications in endocrinology and metabolic diseases such as type 1 and type 2 diabetes mellitus. Its mechanism of action involves agonism at the insulin receptor, thereby stimulating glucose uptake and metabolic regulation. Clinical development focused on evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics, with phase 1 studies conducted in healthy volunteers and people with type 2 diabetes[1][2][3].

Other names

oral insulin NN1954